YAP was suggested to compete with AR binding to transcription factor TEAD, which diminishes the ability of AR to bind to its promoter and enhancer regions leading to reduced expression of AR markers and consequently slower proliferation of prostate cancer cells. This evidence concerns the gene AR and prostate carcinoma.